Rhotekin-2 (RTKN2)

Rhotekin-2 is a member of the rhotekin protein family and functions as an effector protein with homology to Rho-GTPase effectors[1][2]. It contains an N-terminal Rho-GTPase binding domain and a pleckstrin homology (PH) domain. RTKN2 is highly expressed in CD4⁺ T-cells and plays a **key role in lymphocyte survival** by suppressing intrinsic apoptosis through a mechanism that is dependent on the NF-KappaB signaling pathway and regulation of BCL-2 family genes[1]. In cancer biology, RTKN2 has been shown to be upregulated in several malignancies, such as **breast cancer, colon cancer, and ovarian cancer**, where it promotes cell proliferation, inhibits apoptosis, enhances migration and invasion, and activates the Wnt/β-catenin signaling pathway[2]. Knockdown of RTKN2 increases cell death and impairs tumor development, highlighting its potential as a therapeutic target, especially in oncology and immune regulation contexts[1][2]. RTKN2 does not appear to bind the classic RhoA or Rac2 GTPases with detectable affinity in HEK cells, suggesting unique effector functions compared to its close homolog rhotekin[1].

Other names

Rhotekin-2RTKN2PLEKHK1PH domain-containing family K member 1bA531F24.1FLJ39352Em:AC024597.2

Modulation of intrinsic apoptosis via regulation of Bax, Bim, and Bcl-2 genes; dependency on NF-KappaB pathway signaling; modulation of Wnt/β-catenin pathway in cancer cell progression